Breaking News Instant updates and real-time market news.

AUPH

Aurinia Pharmaceuticals

$6.37

0.03 (0.47%)

, RGNX

Regenxbio

$53.02

1.58 (3.07%)

04:55
06/19/19
06/19
04:55
06/19/19
04:55

Raymond James to hold a conference

Life Sciences & MedTech Conference will be held in New York on June 18-19.

AUPH

Aurinia Pharmaceuticals

$6.37

0.03 (0.47%)

RGNX

Regenxbio

$53.02

1.58 (3.07%)

CSII

Cardiovascular Systems

$43.65

1.82 (4.35%)

AERI

Aerie Pharmaceuticals

$33.83

0.52 (1.56%)

COO

Cooper Companies

$324.17

-0.32 (-0.10%)

ICPT

Intercept

$83.03

-1 (-1.19%)

GNMK

GenMark

$6.86

0.05 (0.73%)

ANGO

AngioDynamics

$19.57

0.19 (0.98%)

JNCE

Jounce Therapeutics

$4.84

-0.23 (-4.54%)

DERM

Dermira

$10.04

0.15 (1.52%)

IART

Integra LifeSciences

$51.90

0.7 (1.37%)

CCXI

ChemoCentryx

$8.73

-0.06 (-0.68%)

GRTS

Gritstone Oncology

$10.93

0.58 (5.60%)

ENTA

Enanta

$90.85

1.77 (1.99%)

VYGR

Voyager Therapeutics

$27.82

1.04 (3.88%)

ATEC

Alphatec

$4.40

-0.165 (-3.62%)

  • 19

    Jun

  • 20

    Jun

  • 27

    Jun

  • 10

    Jul

  • 11

    Jul

  • 31

    Jul

  • 01

    Aug

  • 26

    Aug

AUPH Aurinia Pharmaceuticals
$6.37

0.03 (0.47%)

03/20/19
RBCM
03/20/19
NO CHANGE
Target $11
RBCM
Outperform
Aurinia Pharmaceuticals price target raised to $11 from $9 at RBC Capital
RBC Capital analyst Douglas Miehm raised his price target on Aurinia Pharmaceuticals to $11 and kept his Outperform rating. The analyst says the company's Q4 results contained "no surprises" as it remains on track for its phase 3 lupus nephritis trial, with the readout expected later this year. Miehm adds that his higher price target reflects his updated model for positive voclosporin IP developments.
05/23/19
HCWC
05/23/19
NO CHANGE
Target $25
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $25 from $15 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $25 from $15 and reiterates a Buy rating on the shares.
06/04/19
HCWC
06/04/19
NO CHANGE
Target $25
HCWC
Buy
Aurinia board can defeat proxy challenge, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce noted that Aurinia's largest shareholder, ILJIN SNT Co., announced over the weekend that it has launched a proxy contest to elect at least three directors to the company's eight member board. Arce does not agree with ILJIN's claims of excessive compensation, high operating costs or governance failures and believes the current board and new CEO are "well suited" to commercialize voclosporin to its "full potential," he tells investors. The analyst, who said he is confident the current board can defeat this proxy challenge, keeps a Buy rating and $25 price target on Aurinia shares.
03/20/19
CANT
03/20/19
NO CHANGE
Target $24
CANT
Overweight
Aurinia Pharmaceuticals price target raised to $24 from $18 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $24 from $18 and reiterates an Overweight rating on the shares following the company's Q4 results. The new target reflects Aurinia's recent Notice of Allowance regarding a U.S. patent related to voclosporin's method of use. The analyst no longer anticipate a decrease in the voclosporin price in 2027 from generic entry. However, the largest driver of Aurinia's shares will likely be a focus on Phase 3 data for voclosporin for the treatment of lupus nephritis, which could be announced by year-end 2019, says Piros.
RGNX Regenxbio
$53.02

1.58 (3.07%)

02/25/19
02/25/19
UPGRADE
Target $79

Outperform
Regenxbio upgraded to Outperform ahead of catalysts at Evercore ISI
As previously reported, Evercore ISI analyst Josh Schimmer upgraded Regenxbio (RGNX) to Outperform from In Line, with a $79 price target, ahead of some important catalysts this year. While not without risk and important unanswered question, the analyst sees optionality that skews more to the upside. Further, Schimmer believes the Wall Street Journal article suggesting Roche (RHHBY) may bid for Spark Therapeutics (ONCE) will likely lift all gene therapy company shares, including Regenxbio.
06/13/19
RAJA
06/13/19
INITIATION
Target $60
RAJA
Outperform
Regenxbio resumed with an Outperform at Raymond James
Raymond James analyst Dane Leone resumed Regenxbio with an Outperform rating and a price target of $60.
05/07/19
MSCO
05/07/19
NO CHANGE
MSCO
Biogen could rise, or fall, 5% based on Zolgensma label, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Novartis' (NVS) gene therapy for the rare disease spinal muscular atrophy, Zolgensma, is expected to be approved by the FDA this month. He also noted that Biogen's (BIIB) Spinraza is currently the only approved drug for SMA and represents 17% of Biogen's estimated 2019 sales. The public data for Novartis' Zolgensma are only in type 1 patients, or infants, said Harrison, who sees three potential scenarios for the drug's label. In the first, which would involve broad approval across the three patient classes of infants, children and adults, Harrison thinks Novartis shares could be up 1-2%, Biogen could fall about 5%, Ionis (IONS), which receives royalties from Biogen, could be down about 10%, and Regenxbio (RGNX), which will receive royalties from Novartis, could be up 10-15% or more. In the second case, where Zolgensma is granted a Type 1 approval with no restriction, Harrison sees Novartis unchanged, Biogen down 1-3%, Ionis falling 3-5% and Regenxbio rising 5%. In the third scenario, where Zolgensma gets a Type 1 approval but with a weight/age restriction, the analyst thinks Novartis would be down 1-2%, Biogen would be up 2-3%, Ionis could rise 5% and Regenxbio could fall 5-10%. Harrison's base case assumption is that Zolgensma will ultimately capture the majority market share in type 1 patients and a "significant portion" of type 2, or pediatric, patients.
06/05/19
CHDN
06/05/19
NO CHANGE
Target $145
CHDN
Buy
Regenxbio price target raised to $145 from $127 at Chardan
Chardan analyst Gbola Amusa raised his price target for Regenxbio to $145 from $127 ahead of profitability in 2020 on Zolgensma. Amusa notes that analysts are "unwilling" to model Regenxbio's portfolio of 5 internal and 25 external programs, and reiterates a Buy rating on the shares.
CSII Cardiovascular Systems
$43.65

1.82 (4.35%)

08/22/18
STFL
08/22/18
INITIATION
Target $45
STFL
Buy
Cardiovascular Systems initiated with a Buy at Stifel
Stifel analyst Matthew Blackman initiated Cardiovascular Systems with a Buy rating and $45 price target, telling investors in a research note that he believes Cardiovascular Systems' shares are undervalued and sees upside as the company now more-consistently executes against an increasing number of near, intermediate, and longer-term growth-enhancing drivers. Following a challenging FY19, Blackman contends that growth should improve in FY19 back to double-digits, and says growth in FY20 could further accelerate to mid-teen rates due to "multiple" new product and geographic expansion opportunities.
09/19/18
LEER
09/19/18
NO CHANGE
Target $45
LEER
Outperform
Cardiovascular Systems shares poised to move 'meaningfully higher,' says Leerink
Leerink analyst Danielle Antalffy reiterates an Outperform rating and $45 price target on Cardiovascular Systems after hosting meetings with management. The meetings reinforced the analyst's view that the company represents a sustainable double-digit growth story for the next few years. She continues to believe Cardiovascular Systems has a "significant" competitive advantage in both calcified and below-the-knee lesions within Peripheral that should drive above-market growth. The shares are poised to move "meaningfully higher" as management drives back toward a sustainable mid-teens sales growth range, Antalffy tells investors in a research note.
04/11/19
BOFA
04/11/19
DOWNGRADE
BOFA
Underperform
Cardiovascular Systems downgraded to Underperform on valuation at BofA/Merrill
BofA/Merrill analyst Bob Hopkins downgraded Cardiovascular Systems to Underperform and lowered its price target to $42 from $51. Hopkins changed his view citing mostly valuation following recent share outperformance, but expects the competitive landscape to intensify in 2020 and 2021.
08/22/18
08/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BJ's Restaurants (BJRI) initiated with a Buy at Maxim. 2. Nightstar Therapeutics (NITE) initiated with a Buy at Janney Montgomery Scott. 3. Endava (DAVA) initiated with a Hold at Deutsche Bank. 4. Cardiovascular Systems (CSII) initiated with a Buy at Stifel. 5. Wright Medical (WMGI) initiated with a Buy at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AERI Aerie Pharmaceuticals
$33.83

0.52 (1.56%)

06/11/19
ADAM
06/11/19
NO CHANGE
Target $56
ADAM
Buy
Aerie Pharmaceuticals Q2 script numbers too high, says Canaccord
Canaccord analyst Dewey Steadman said Aerie Pharmaceuticals' Rhopressa and Rocklatan prescriptions were likely impacted by the Memorial Day holiday. As a result, the analyst does not believe the prescription run rate can meet his/consensus revenue expectations for the quarter and that estimates will likely need to come down ahead of its Q2 results. Steadman maintained his Buy rating and $56 price target on Aerie Pharmaceuticals shares.
06/11/19
CANT
06/11/19
NO CHANGE
Target $85
CANT
Overweight
Aerie drugs transforming glaucoma treatment space, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros says that with a year's worth of scripts reported for Rhopressa and an early first month look at the Rocklatan launch, he remains confident that Aerie Pharmaceuticals' two drugs are transforming the glaucoma treatment space. With "superior efficacy established" over the number-one prescribed prostaglandin, Aerie's portfolio of glaucoma treatments is best in class, Piros tells investors in a research note. He reiterates an Overweight rating on the shares with an $85 price target.
05/09/19
STFL
05/09/19
NO CHANGE
STFL
Buy
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
Stifel analyst Annabel Samimy said Novartis' (NVS) agreement to buy Takeda's (TAK) dry eye product Xiidra for $3.4B upfront in cash and up to an additional $1.9B in potential milestone payments "clearly frames the value for innovative ophthalmologic assets" and makes shares of Aerie Pharmaceuticals (AERI) "look like a steal." Applying the same peak sales multiple that Novartis paid for Xiidra implies a market-value of greater than $6B for Aerie, said Samimy, who noted that she does not expect an immediate takeout of Aerie but remains a buyer of the shares.
05/10/19
ADAM
05/10/19
NO CHANGE
Target $56
ADAM
Buy
Aerie Pharmaceuticals price target cut to $56 from $65 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target for Aerie Pharmaceuticals to $56 from $65 following the company's Q1 results, saying Aerie posted a sequential revenue decline from Q4 and a top- line miss relative to consensus expectations as growth from Rhopressa meaningfully slowed from its post-launch ramp last year. In a research note to investors, Steadman says he thinks Aerie will be highly dependent on a return to Rhopressa growth coupled with exceptionally strong Rocklatan launch metrics to meet its $110M-$120M 2019 revenue guide after posting only ~$11M in Q1 revenue. Steadman "reluctantly" maintains a Buy rating, saying the need to flawlessly execute, coupled with a lack of binary pipeline catalysts, leave him to believe that Aerie shares will likely be rangebound for the near future.
COO Cooper Companies
$324.17

-0.32 (-0.10%)

06/03/19
NRCS
06/03/19
NO CHANGE
Target $340
NRCS
Buy
Cooper Companies price target raised to $340 from $331 at Northcoast
Northcoast analyst David Keiser reiterated a Buy rating on Cooper Companies and raised his price target to $340 from $331 following the company's Q2 results, saying the company delivered largely positive Q2 results, including continued "strong" organic growth for CooperVision and ParaGard. In a research note to investors, Keiser says he is "encouraged" b y the company's expectation for improved CooperVision Americas organic growth in the second half of the year.
05/31/19
PIPR
05/31/19
NO CHANGE
Target $330
PIPR
Overweight
Cooper Companies target raised to $330 on 'good' quarter at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Cooper Companies to $330 from $325 saying the company reported an "overall good quarter." Currency again had an impact in the quarter but underlying proforma growth for CooperVision was 8% and 6% for CooperSurgical, which are "both solid," O'Brien tells investors in a research note. He keeps an Overweight rating on Cooper Companies.
06/10/19
WELS
06/10/19
NO CHANGE
Target $356
WELS
Outperform
Cooper Companies price target raised to $356 from $325 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Cooper Companies to $356 from $325 after meeting with management. The analyst notes that management seems confident on its 2019 outlook and continue growth momentum, 2020 EPS growth could reach 10% despite anticipated tax rate increase, contact lens market should continue to grow 5%-plus for the foreseeable future, and management is particularly excited about the long-term prospect of myopia management lenses. Biegelsen reiterates an Outperform rating on the shares.
04/05/19
PIPR
04/05/19
NO CHANGE
Target $325
PIPR
Overweight
Piper a 'little cautious' on Q2 results for Cooper Companies
After speaking with a contact lens distributor, Piper Jaffray analyst Matt O'Brien is a "little cautious" on Cooper Companies' fiscal Q2 results. The shift to dailies continues, which is positive for the market as a whole, but Johnson & Johnson (JNJ) and Alcon were more aggressive in calendar Q1, so results for the category "may be a bit unusual," O'Brien tells investors in a research note. In addition to the "odd activity" from the two largest players, the analyst also heard about some "aggressive behavior" from Cooper in recent weeks, which makes him think the company should hit its numbers. He's still bullish on Cooper Companies capturing share in lenses in 2019 and 2020 and keeps an Overweight rating on the name.
ICPT Intercept
$83.03

-1 (-1.19%)

06/06/19
RAJA
06/06/19
NO CHANGE
Target $183
RAJA
Strong Buy
Raymond James questions accelerated 'F4 NASH' approval for Intecerpt
Raymond James analyst Steven Seedhouse noted that the FDA published new guidance on development of drugs to treat NASH with compensated cirrhosis, otherwise known as "F4 NASH," which is being studied in Intercept's ongoing REVERSE study. The guidance suggests to him that an interim analysis assessing improvement in fibrosis and other secondary histologic endpoints at 52 weeks may not be sufficient for accelerated approval, Seedhouse tells investors. However, he adds that he doesn't think this has any impact on accelerated approval in non-cirrhotic NASH, which is the group being studied in the REGENERATE trial. Seedhouse keeps a Strong Buy rating and $183 price target on Intercept shares.
06/06/19
RAJA
06/06/19
NO CHANGE
RAJA
Strong Buy
Door not completely closed for Intercept on F4 NASH accelerated approval, says Raymond James
Raymond James analyst Steven Seedhouse notes that he has discussed the FDA draft guidance for the development of drugs for treatment of NASH with compensated cirrhosis with Intercept management. The analyst believes that some details seem to leave open the possibility for accelerated approval in F4 NASH based on REVERSE, which is essentially predicated on written agreement that Intercept received from FDA prior to starting the REVERSE study that informed/informs the intention that REVERSE will serve as the basis for seeking initial U.S. and international marketing authorizations of OCA for the treatment of NASH patients with compensated cirrhosis. Seedhouse reiterates a Strong Buy rating on the shares.
06/13/19
RBCM
06/13/19
NO CHANGE
RBCM
RBC says recent worries about Intercept's accelerated approval 'unfounded'
RBC Capital analyst Brian Abrahams said that at an investor conference yesterday night Intercept's CEO said the company has communicated with the FDA since the agency released draft guidance on development of drugs to treat NASH with compensated cirrhosis. The CEO said, according to Abrahams, that the FDA offered definitive confirmation that histological endpoints can still form the basis of accelerated approval from the REVERSE study. The analyst, who said Wall Street may be "overlooking" this new update, points to the comments as added evidence that concerns about accelerated approval have been "unfounded."
06/06/19
BARD
06/06/19
NO CHANGE
Target $227
BARD
Outperform
Intercept weakness unwarranted after FDA guidance, says Baird
With Intercept shares down 6.5% to $78.92 in afternoon trading following the release of draft guidance from the FDA on development of drugs to treat NASH with compensated cirrhosis, Baird analyst Brian Skorney said the pullback was "unwarranted" and "silly." The guidance doesn't impact Intercept's primary market opportunity, which will specifically be in F2 and F3 NASH patients, said Skorney, who thinks the market is misinterpreting the risk here as applying to the primary NASH approval. The analyst, who believes the new guidance "has zero impact" on OCA approvability in F2/3 NASH, suggests buying the stock on weakness and keeps an Outperform rating and $227 price target on Intercept shares.
GNMK GenMark
$6.86

0.05 (0.73%)

10/23/18
RAJA
10/23/18
INITIATION
Target $7
RAJA
Outperform
GenMark resuming with an Outperform at Raymond James
Raymond James analyst John Hsu resumed coverage on GenMark with an Outperform and $7 price target telling investors it is a leading molecular diagnostics company with a compelling sample-to-answer platform and is forecasting drive solid double-digit revenue growth through 2020
12/21/18
WBLR
12/21/18
NO CHANGE
WBLR
Outperform
GenMark selloff brings 'compelling' valuation, says William Blair
William Blair analyst Brian Weinstein says the recent pullback in shares of GenMark Diagnostics brings a "compelling" valuation. The company' 510(k) clearance from the FDA for its ePlex Blood Culture Identification Gram-Positive panel is "another step toward building a broader menu," Weinstein tells investors in a research note. . This is a "nice year-end win for the company and we believe deserves to be recognized by investors," adds the analyst. He believes the long-term success of GenMark largely depends on its ability to drive placements of its ePlex system, which will likely be dictated by the number of panels that can be run on the system. Weinstein thinks yesterday's news should be seen as a positive update for shares. He keeps an Outperform rating on GenMark.
07/31/18
ADAM
07/31/18
NO CHANGE
Target $10
ADAM
Buy
GenMark Q2 indicates company on track with growth initiatives, says Canaccord
Canaccord analyst Mark Massaro said GenMark delivered solid Q2 results, indicating the company remains on track with its growth initiatives. He said the outlook should help build investor confidence throughout the balance of the year and he continues to believe that a multi-billion dollar opportunity awaits. Massaro reiterated his Buy rating and raised his price target to $10 from $9 on GenMark shares.
ANGO AngioDynamics
$19.57

0.19 (0.98%)

07/11/18
RAJA
07/11/18
DOWNGRADE
RAJA
Market Perform
AngioDynamics downgraded to Market Perform from Outperform at Raymond James
07/12/18
ADAM
07/12/18
NO CHANGE
Target $20
ADAM
Hold
AngioDynamics price target raised to $20 from $17 at Canaccord
Canaccord analyst Jason Mills reiterated a Hold rating on AngioDynamics and raised his price target to $20 following the company's "fairly in-line" quarter, telling investors in a research note that lack of upside, along with a "somewhat lackluster" guide for FY19 drove a sell-off in the stock post print. While Mills thinks the company is better positioned operationally today than it was two years ago when CEO Clemmer took over the helm, growth remains the key piece missing from the story. The analyst believes NanoKnife is the company's biggest opportunity and potential growth driver, but thinks it will be a few years before it can provide meaningful contributions to AngioDynamics' top line.
04/01/19
KEYB
04/01/19
UPGRADE
KEYB
Overweight
AngioDynamics upgraded to Overweight from Sector Weight at KeyBanc
JNCE Jounce Therapeutics
$4.84

-0.23 (-4.54%)

11/14/18
JPMS
11/14/18
DOWNGRADE
JPMS
Underweight
JPMorgan downgrades Jounce to Underweight on lack of catalysts
JPMorgan analyst Cory Kasimov last night downgraded Jounce Therapeutics to Underweight from Neutral without a price target. It may take the company some time to generate substantial enough clinical data to prompt investors to reengage, Kasimov tells investors in a research note following the company's Q3 results. While the company is well capitalized and has a compelling approach to drug development, Jounce shares could continue to be a relative underperformer given a lack of meaningful clinical catalysts, says the analyst.
11/13/18
JPMS
11/13/18
DOWNGRADE
JPMS
Underweight
Jounce Therapeutics downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov downgraded Jounce Therapeutics to Underweight from Neutral.
08/13/18
HCWC
08/13/18
NO CHANGE
Target $13
HCWC
Buy
Jounce Therapeutics price target lowered to $13 from $19 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Jounce Therapeutics to $13 but keeps a Buy rating on the shares. The analyst sees limited near-term catalysts to drive investor sentiment, and he believes there remains "substantial clinical questions that need to be addressed before ICOS agonism comes back to the fore."
06/28/18
RAJA
06/28/18
INITIATION
Target $13
RAJA
Outperform
Jounce Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated Jounce Therapeutics with an Outperform and $13 price target.
DERM Dermira
$10.04

0.15 (1.52%)

06/06/19
MZHO
06/06/19
UPGRADE
Target $14
MZHO
Buy
Dermira upgraded to Buy from Neutral at Mizuho
Mizuho analyst Irina Koffler upgraded Dermira to Buy from Neutral while lowering her price target for the shares to $14 from $17. The analyst expects Almirall to exercise its European rights to lebrikizumab and she sees potential upside from other strategic alternatives. She attributes the 40% share selloff since April to financing uncertainty and the "lackluster" performance of Qbrexza. However, she views Dermira's risk/reward as favorable into Almirall's decision. The stock trades in-line with Koffler's $9 bear-case scenario, which assumes that Almirall opts out of the deal.
04/18/19
CANT
04/18/19
NO CHANGE
Target $25
CANT
Overweight
Cantor sees 'golden egg' potential in Dermira, boosts price target to $25
Cantor Fitzgerald analyst Louise Chen raised her price target for Dermira to $25 from $20 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 14c to $11.27. Peak sales potential of Qbrexza for hyperhidrosis and lebrikizumab for atopic dermatitis are underappreciated, Chen tells investors in a research note ahead of the long Easter weekend titled "We Think This Bunny Could Lay The Golden Egg." The analyst also thinks Dermira is an "interesting company in a consolidating space." Her new price target reflects the inclusion of Lebrikizumab sales following the positive Phase 2b data readout earlier this year.
04/18/19
CANT
04/18/19
NO CHANGE
Target $25
CANT
Overweight
Dermira price target raised to $25 from $20 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen raised her price target on Dermira to $25 as she is now including an estimate for sales for lebrikizumab following the positive Phase 2b data readout in atopic dermatitis. Chen keeps an Overweight rating on Dermira shares.
03/27/19
HCWC
03/27/19
NO CHANGE
Target $22
HCWC
Buy
Dermira price target raised to $22 from $13 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised his price target for Dermira to $22 from $13 saying the company last week announced "very strong" data from the Phase 2B Treble study for lebrikizumab in the treatment of atopic dermatitis. The data arguably represents a "best case" scenario for Dermira, Tsao tells investors in a research note. The results were "sufficiently compelling to put to rest any debate" whether the company should move into lebrikizumab into Phase 3 testing, contends the analyst. He raised his peak sales estimate for lebrikizumab to $2.5B, up from $1.5B, and keeps a Buy rating on Dermira.
IART Integra LifeSciences
$51.90

0.7 (1.37%)

04/25/19
OPCO
04/25/19
NO CHANGE
Target $65
OPCO
Outperform
Integra LifeSciences price target lowered to $65 from $70 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Integra LifeSciences to $65 from $70 following quarterly results on recent peer multiple contraction. The analyst reiterates an Outperform rating on the shares.
01/03/19
RHCO
01/03/19
INITIATION
Target $56
RHCO
Buy
Integra LifeSciences initiated with a Buy at SunTrust
SunTrust analyst Bruce Nudell initiated Integra LifeSciences with a Buy rating and a price target of $56, saying the "temporary" headwinds experienced by the company in Q3 and the subsequent pullback in its stock price present a "buying opportunity". The analyst cites the company's progress in integrating its "Codman acquisition, expanding its geographic footprint, augmenting and optimizing its distribution channels and introducing new products that should drive 5.5% organic growth over the 2018-22 timeframe."
03/11/19
PIPR
03/11/19
NO CHANGE
Target $62
PIPR
Overweight
Integra warning letter 'not the end of the world,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says he spoke to Integra LifeSciences after the company disclosed a warning letter relating to its wound care manufacturing facility in Boston. The company emphasized that there were no safety issues associated with the products, O'Brien tells investors in a research note. The analyst does not expect the letter to impact revenue much, if at all. Management believes that it will be able to have the issue resolved within about six months, he adds. These FDA warnings letters happen, and is "not the end of the world" for Integra's wound care business, says O'Brien. He keeps an Overweight rating on Integra LifeSciences with a $62 price target.
02/21/19
02/21/19
NO CHANGE

Piper reiterates Overweight rating on Integra after Q4 earnings
Piper Jaffray analyst Matt O'Brien reiterated an Overweight rating and $62 price target on Integra LifeSciences after the company reported better-than-expected Q4 earnings, including Q4 sales of $383.3M which represented growth of ~4% and was on the higher end of the company's preannounced range of $378-383M. Additionally, Integra guided for FY19 adjusted earnings of $2.64-$2.72, ahead of Piper's previous estimate of $2.61.
CCXI ChemoCentryx
$8.73

-0.06 (-0.68%)

06/06/19
RAJA
06/06/19
NO CHANGE
Target $17
RAJA
Strong Buy
ChemoCentryx price target lowered to $17 from $24 at Raymond James
Raymond James analyst Steven Seedhouse removed hidradenitis suppurativa from his model for ChemoCentryx (CCXI) after InflaRx (IFRX) reported that its Phase IIb trial for C5a antibody IFX-1 failed, leading him to lower his price target on the shares to $17 from $24. However, he keeps a Strong Buy rating on ChemoCentryx shares and said he would be a buyer amid the weakness, citing Phase 2 data for avacopan in AAV and a near-term Phase 3 data readout for AAV in Q4.
06/06/19
ADAM
06/06/19
NO CHANGE
Target $14
ADAM
Buy
ChemoCentryx price target lowered to $14 from $20 at Canaccord
Canaccord analyst Michelle Gilson lowered her price target on ChemoCentryx to $14 from $20 following the failure of IFX-1 failing to validate the C5a hypothesis in HS. The analyst believes AAV (associated vasculitis) remains a better indication than HS and is central to his buy thesis. Gilson maintained her Buy rating on ChemoCentryx shares.
06/05/19
PIPR
06/05/19
NO CHANGE
Target $17
PIPR
Overweight
Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure
Piper Jaffray analyst Edward Tenthoff lowered his price target for ChemoCentryx (CCRX) to $17 from $20 after its competitor InflaRx (IFRX) reported negative Phase IIb data for C5a antibody IFX-1 to treat moderate-to-severe hidradenitis suppurativa. ChemoCentryx shares are down because the company has its own small molecule avacopan targeting C5a receptor in an ongoing Phase II hidradenitis suppurativa study with data in 2020, Tenthoff tells investors in a research note. The analyst says that while nuances exist between InflaRx's IFX-1 and ChemoCentryx's avocopan for receptor coverage and distribution, the lack of dose response in InflaRx's Phase II data raises concern over the relevancy of C5a in hidradenitis suppurativa. As a result, Tenthoff removed value for avacopan in hidradenitis suppurativa in his model but remains a buyer of ChemoCentryx shares for the Phase III Advocate avacopan data in ANCA-associated vasculitis in Q4 of this year. He keeps an Overweight rating on the shares, which are down 17% to $9.18 in afternoon trading.
06/05/19
06/05/19
DOWNGRADE

Market Perform
InflaRx downgraded to Market Perform on HS study results at Raymond James
As previously reported, Raymond James analyst Steven Seedhouse downgraded InflaRx (IFRX) to Market Perform from Outperform as it is now trading below cash and thereby baking in what he believes is an appropriate value, which is zero value for hidradenitis suppurativa and risk to all follow-on indications in the pipeline for IFX-1. The analyst acknowledges that HS may not be a viable indication for C5a pathway inhibition, which seems "quite clear from InflaRx's failed study." Seedhouse adds that there is "obvious negative read-through" to Chemocyntrx (CCXI), which is running a large Phase 2 randomized study in HS for avacopan. He expects that study to at a minimum fail or maybe even be stopped early given the complete lack of signal demonstrated by IFX-1.
GRTS Gritstone Oncology
$10.93

0.58 (5.60%)

12/11/18
BTIG
12/11/18
NO CHANGE
Target $31
BTIG
Buy
Gritstone Oncology price target raised to $31 from $26 at BTIG
BTIG analyst Thomas Shrader raised his price target on Gritstone Oncology to $31 and kept his Buy rating after the company's "announced start of lead optimization of a neoantigen-targeted bi-mAb designed to bring T-Cells to neoantigen targets on tumors." The analyst has a favorable view of this program and sees its selection of specific neoantigen targets for lead optimization as a "significant step in the development of neoantigen-targeted therapeutics."
03/27/19
BREN
03/27/19
INITIATION
Target $30
BREN
Buy
Gritstone Oncology initiated with a Buy at Berenberg
Berenberg analyst Shanshan Xu initiated Gritstone Oncology with a Buy rating and $30 price target, stating that Gritstone's neoantigen platform may represent the "best-in-class" algorithm for identifying bona fide neoantigens. The company also has a vaccine "prime-and-boost" platform that may also be differentiated, Xu noted.
03/14/19
RAJA
03/14/19
INITIATION
RAJA
Outperform
Gritstone Oncology initiated with an Outperform at Raymond James
Raymond James analyst Dane Leone initiated Gritstone Oncology with an Outperform rating and a price target of $20. The analyst has three key reasons for recommending the stock: First, GRANITE-001 will be a proof of concept regarding the anti-tumor effect of highly stimulated CD8+ T cells. Second, "development of the MHC Class II EDGE model balances the risks with the current reliance of CD8+ T cells within the GRANITE-001 and SLATE-001 programs." Third, Leone believes the technical approach to neoantigen vaccine design that Gritstone is pursuing is "likely to be more effective than competitor efforts employing peptide vaccination approaches."
03/07/19
HCWC
03/07/19
INITIATION
Target $17
HCWC
Buy
Gritstone Oncology initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Gritstone Oncology with a Buy rating and $17 price target. The company's core technology is its Gritstone EDGE artificial intelligence platform, which has demonstrated an up to nine-fold increased prediction accuracy for identifying potential tumor neoantigens, Ramakanth tells investors in a research note. Further, Granite-001 has the potential to become the first "universal" vaccine that can be used across the full range of cancer indications, which could significantly increase its market potential, says the analyst.
ENTA Enanta
$90.85

1.77 (1.99%)

04/15/19
JMPS
04/15/19
NO CHANGE
Target $116
JMPS
Outperform
Enanta early data on EDP-514 look promising, says JMP Securities
JMP Securities analyst Liisa Bayko said she was impressed with the preclinical data presented by Enanta (ENTA) at the EASL meeting on its HBV core inhibitor candidate EDP-514. When comparing to other core inhibitors in development, EDP-514 "appears at least as potent as the competition" with the exception of Assembly Biosciences' (ASMB) third-generation capsid inhibitor ABI-H3733, said Bayko, who added that EDP-514 has a superior reduction in HBV viral load than ABI-H3733 and a lower EC50 level than Assembly's first- and second-generation inhibitors. Bayko keeps an Outperform rating and $116 price target on Enanta shares.
04/23/19
BREN
04/23/19
UPGRADE
BREN
Buy
Enanta upgraded to Buy from Hold at Berenberg
12/13/18
12/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) assumed with a Buy at Mizuho. 2. Molson Coors (TAP) and Keurig Dr Pepper (KDP) were initiated with a Buy at UBS, while PepsiCo (PEP) and Constellation Brands (STZ) were initiated with a Neutral, and Monster Beverage (MNST) and Boston Beer (SAM) were initiated with a Sell. 3. SeaSpine (SPNE) initiated with an Outperform at Wells Fargo. 4. XPO Logistics (XPO) initiated with a Buy at SunTrust. 5. Enanta (ENTA) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/19
WOLF
05/24/19
INITIATION
Target $117
WOLF
Outperform
Enanta initiated with an Outperform at Wolfe Research
Wolfe Research initiated Entana with an Outperform and $117 price target.
VYGR Voyager Therapeutics
$27.82

1.04 (3.88%)

03/06/19
CANT
03/06/19
INITIATION
Target $27
CANT
Overweight
Voyager Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Voyager Therapeutics with an Overweight rating and $27 price target. The analyst believes Voyager's "innovative" gene-therapy-based drug candidates for several debilitating central nervous system diseases "could prove transformational." He sees "immense potential" in Voyager's platform of AAV-based gene delivery.
03/06/19
03/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Voyager Therapeutics (VYGR) initiated with an Overweight at Cantor Fitzgerald. 2. L.B. Foster (FSTR) initiated with a Buy at B. Riley FBR. 3. Raymond James (RJF) initiated with a Buy at Argus. 4. Chegg (CHGG) initiated with a Buy at Berenberg. 5. Pinduoduo (PDD) initiated with a Buy at UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/19
HCWC
05/08/19
NO CHANGE
Target $26
HCWC
Buy
Voyager Therapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Voyager Therapeutics to $26 from $22 saying execution was the consistent theme during the company's Q1 results. The analyst sees a "solid" balance sheet and "compelling" partnerships. He keeps a Buy rating on the shares.
06/18/19
WEDB
06/18/19
NO CHANGE
Target $36
WEDB
Outperform
Voyager Therapeutics price target raised to $36 from $27 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Voyager Therapeutics to $36 from $27 as we begin to incorporate Huntington's disease gene therapy candidate VY-HTT01 into his valuation, assigning it a preliminary program valuation of about $9.5/share. The analyst reiterates an Outperform rating on the shares.
ATEC Alphatec
$4.40

-0.165 (-3.62%)

04/10/19
LSCM
04/10/19
NO CHANGE
Target $7
LSCM
Buy
Investors 'missing the boat' with Alphatec, says Lake Street
After speaking time with management, Lake Street analyst Brooks O'Neil affirms a Buy rating on Alphatec shares with a $7 price target. The analyst believes investors remain skeptical that the company's new team can generate "rapid revenue growth and has sufficient capital to transform its business." However, he thinks management will drive 30%-plus sales growth with Alphatec's new Informatics Platform and 12 new products scheduled to launch later this year. "Skeptical investors are missing the boat," O'Neil tells investors in a research note.
02/12/19
LSCM
02/12/19
NO CHANGE
Target $7
LSCM
Buy
Alphatec transformation on track despite share weakness, says Lake Street
Lake Street analyst Brooks O'Neil believes his fundamental thesis on Alphatec (ATEC) is playing out despite the recent weakness in the shares. CEO Pat Miles and his team are spine experienced and taking "significant steps" to strengthen the company's distributor relationships and to revitalize its product line, O'Neil tells investors in a research note. Initial feedback on new products has been very positive, says the analyst. He affirms his Buy rating on Alphatec with a $7 price target. Further, following reports of Smith & Nephew's (SNN) interest in NuVasive (NUVA), O'Neil says one of the larger players in the spine space "might take a run at" Alphatec should its transformation continue as he expects.

TODAY'S FREE FLY STORIES

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.